NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
Stock data | 2024 | Change |
---|---|---|
Price | $1.24 | N/A |
Market Cap | $24.58M | N/A |
Shares Outstanding | 19.77M | N/A |
Employees | 100.00 | N/A |